

Jin Seok Ahn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3774820/publications.pdf>

Version: 2024-02-01

254
papers

7,669
citations

61984

43
h-index

76900

74
g-index

258
all docs

258
docs citations

258
times ranked

11414
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of the Korean Version of the Patient-Reported Outcomes Measurement Information System 29 Profile V2.1 among Cancer Survivors. <i>Cancer Research and Treatment</i> , 2022, 54, 10-19.	3.0	7
2	Long-term Survival in Non-“Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment. <i>Cancer Research and Treatment</i> , 2022, 54, 150-156.	3.0	0
3	Who is more likely to adopt and comply with the electronic patient-reported outcome measure (ePROM) mobile application? A real-world study with cancer patients undergoing active treatment. <i>Supportive Care in Cancer</i> , 2022, 30, 659-668.	2.2	6
4	Efficacy of a tailored moisturizer for reducing chemotherapy-induced skin dryness in breast cancer patients: A randomized controlled clinical trial. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 858-860.	1.2	1
5	Development and Validation of Digital Health Technology Literacy Assessment Questionnaire. <i>Journal of Medical Systems</i> , 2022, 46, 13.	3.6	14
6	ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer. <i>Investigational New Drugs</i> , 2022, 40, 265.	2.6	2
7	Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2321-2328.	7.0	7
8	Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience. <i>Cancer Research and Treatment</i> , 2022, , .	3.0	8
9	Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 415-425.	0.8	9
10	A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2022, 17, 558-567.	1.1	43
11	Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor. <i>Oncology</i> , 2022, 100, 228-237.	1.9	2
12	Abstract P1-18-32: A nationwide real-world study for evaluation of efficacy and safety of T-DM1 in patients with HER2-positive locally-advanced unresectable or metastatic breast cancer in Korea (KCSG) Tj ETQq0 0 0.gBT /Overlock 10 T		
13	Abstract P3-13-08: Fusion analysis including NTRK fusion in breast cancers (BC): From RNASeq data analysis from 629 BC tissue samples. <i>Cancer Research</i> , 2022, 82, P3-13-08-P3-13-08.	0.9	0
14	Abstract P2-13-04: Final survival analysis of a phase 3 study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer. <i>Cancer Research</i> , 2022, 82, P2-13-04-P2-13-04.	0.9	2
15	Temporal patterns of chronic disease incidence after breast cancer: a nationwide population-based cohort study. <i>Scientific Reports</i> , 2022, 12, 5489.	3.3	4
16	Artificial Intelligence-“Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1916-1928.	1.6	94
17	Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 900-908.	1.1	23
18	Longitudinal monitoring by next-generation sequencing of plasma cell-free <sc>DNA</sc> in <sc>ALK</sc> rearranged <sc>NSCLC</sc> patients treated with <sc>ALK</sc> tyrosine kinase inhibitors. <i>Cancer Medicine</i> , 2022, 11, 2944-2956.	2.8	24

#	ARTICLE	IF	CITATIONS
19	Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer. <i>European Journal of Cancer</i> , 2022, 169, 42-53.	2.8	10
20	The 10-year journey of non-“small cell lung cancer: A real-world experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9133-9133.	1.6	0
21	Exploratory analysis using cfDNA-based fragmentomics to predict disease recurrence in limited disease small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8569-8569.	1.6	0
22	Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC. <i>Clinical Cancer Research</i> , 2022, 28, 4312-4321.	7.0	7
23	Patient-Reported Outcomes Measurement Information System: Translation and Linguistic Validation of Six Profile Domains for Korean Adults. <i>Journal of Korean Medical Science</i> , 2021, 36, e212.	2.5	3
24	Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea. <i>Diagnostics</i> , 2021, 11, 370.	2.6	2
25	Abstract PS10-38: Real World Evidence (RWE) of neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in patients with HER2 positive early or locally advanced breast cancer treated Single institutional experience. , 2021, , .		0
26	Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors. <i>Translational Lung Cancer Research</i> , 2021, 10, 878-888.	2.8	4
27	Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-“small cell lung cancer. <i>European Journal of Immunology</i> , 2021, 51, 956-964.	2.9	15
28	Abstract P20: Continuity of oncology clinical trials during the Coronavirus Disease-2019 pandemic in Korea. , 2021, , .		0
29	The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 653243.	2.8	1
30	Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery. <i>Journal of Korean Neurosurgical Society</i> , 2021, 64, 271-281.	1.2	8
31	High concordance of actionable genomic alterations identified between circulating tumor DNA-“based and tissue-“based next-“generation sequencing testing in advanced non-“small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program. <i>Cancer</i> , 2021, 127, 3019-3028.	4.1	37
32	A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumor (KCSG Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	2
33	Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry. <i>Frontiers in Oncology</i> , 2021, 11, 596364.	2.8	14
34	The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8562-8562.	1.6	5
35	Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 747-757.	2.5	10
36	Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype. <i>Clinical Breast Cancer</i> , 2021, 21, e402-e414.	2.4	2

#	ARTICLE	IF	CITATIONS
37	Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 37, 102415.	3.3	16
38	Real-time automatically updated data warehouse in healthcare (ROOT): an innovative and automated data collection system. <i>Translational Lung Cancer Research</i> , 2021, 10, 3865-3874.	2.8	4
39	Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?. <i>Frontiers in Oncology</i> , 2021, 11, 759150.	2.8	7
40	Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 5260.	3.7	11
41	Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience. <i>European Journal of Cancer</i> , 2021, 159, 167-173.	2.8	6
42	Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach. <i>Cancers</i> , 2021, 13, 5835.	3.7	6
43	Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment. <i>Translational Lung Cancer Research</i> , 2021, 10, 4209-4220.	2.8	6
44	Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study. <i>Blood Cancer Journal</i> , 2021, 11, 200.	6.2	6
45	Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. <i>Investigational New Drugs</i> , 2020, 38, 360-368.	2.6	32
46	Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT). <i>Supportive Care in Cancer</i> , 2020, 28, 1829-1837.	2.2	3
47	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 139, 22-27.	2.0	22
48	Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). <i>Journal of Clinical Oncology</i> , 2020, 38, 488-495.	1.6	233
49	Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. <i>Clinical Lung Cancer</i> , 2020, 21, e182-e190.	2.6	5
50	Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity. , 2020, 8, e001199.		7
51	Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?. <i>Biology</i> , 2020, 9, 326.	2.8	6
52	The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1749-1758.	2.8	14
53	Metabolic radiogenomics in lung cancer: associations between FDG PET image features and oncogenic signaling pathway alterations. <i>Scientific Reports</i> , 2020, 10, 13231.	3.3	11
54	Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1059-1067.	4.1	2

#	ARTICLE	IF	CITATIONS
55	Evaluating entrectinib as a treatment option for non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1935-1942.	1.8	8
56	Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1758-1766.	1.1	60
57	Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 325-334.	2.5	18
58	Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?. <i>Journal of Thoracic Disease</i> , 2020, 12, 3796-3803.	1.4	19
59	Regulatory (FoxP3+) T cells and TGF- β 2 predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 18994.	3.3	52
60	Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With <i>MET</i> Exon 14 Skipping. <i>In Vivo</i> , 2020, 34, 1399-1406.	1.3	10
61	Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. <i>Nature Communications</i> , 2020, 11, 2285.	12.8	565
62	Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma. <i>European Journal of Cancer</i> , 2020, 132, 150-158.	2.8	28
63	Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience. <i>Cancers</i> , 2020, 12, 1306.	3.7	0
64	Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 146, 23-29.	2.0	87
65	Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 1315-1325.	3.4	8
66	MDSC subtypes and CD39 expression on CD8 ⁺ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. <i>European Journal of Immunology</i> , 2020, 50, 1810-1819.	2.9	57
67	Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime automatically updated data warehouse in health care; Tj ETQq1 1 0.784314ogBT/Oerlock 1	1.0	1
68	Genomic landscape of acquired resistance to third-generation <i>EGFR</i> tyrosine kinase inhibitors in <i>EGFR</i> T790M-mutant non-small cell lung cancer. <i>Cancer</i> , 2020, 126, 2704-2712.	4.1	26
69	Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy. <i>Cancer</i> , 2020, 126, 4002-4012.	4.1	22
70	PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence. <i>Cancer Medicine</i> , 2020, 9, 2352-2362.	2.8	29
71	Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. <i>Nature Communications</i> , 2020, 11, 951.	12.8	34
72	Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. <i>Oncology</i> , 2020, 9, 1722023.	4.6	37

#	ARTICLE	IF	CITATIONS
73	Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice. Japanese Journal of Clinical Oncology, 2020, 50, 594-601.	1.3	23
74	Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors. BMC Ophthalmology, 2020, 20, 19.	1.4	32
75	First-in-human phase I study of ALT-P7, a HER2-targeting antibody-drug conjugate in patients with HER2-positive advanced breast cancer.. Journal of Clinical Oncology, 2020, 38, 3551-3551.	1.6	24
76	Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.. Journal of Clinical Oncology, 2020, 38, 9603-9603.	1.6	5
77	KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2020, 38, TPS596-TPS596.	1.6	12
78	Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea. Cancer Research and Treatment, 2020, 52, 292-300.	3.0	17
79	Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting. Cancer Research and Treatment, 2020, 52, 907-916.	3.0	12
80	<i>EGFR</i> C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with <i>EGFR</i> T790M Mutation. Cancer Research and Treatment, 2020, 52, 1288-1290.	3.0	12
81	Characteristics of female lung cancer in Korea: analysis of Korean National Lung Cancer Registry. Journal of Thoracic Disease, 2020, 12, 4612-4622.	1.4	4
82	Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs. Immune Network, 2020, 20, e48.	3.6	10
83	Clinical features and prognosis of breast cancer with gastric metastasis. Oncology Letters, 2019, 17, 1833-1841.	1.8	13
84	Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 446-454.	6.4	75
85	Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib. Cancer Research and Treatment, 2019, 51, 502-509.	3.0	74
86	DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC. Journal of Thoracic Oncology, 2019, 14, 1640-1650.	1.1	64
87	Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry. Journal of Global Oncology, 2019, 5, 1-9.	0.5	13
88	Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-â€œSmall Cell Lung Cancer Treated With Immune Checkpoint Inhibitor. Journal of Thoracic Oncology, 2019, 14, 1608-1618.	1.1	78
89	Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1â€œ2 study. Lancet Oncology, The, 2019, 20, 1681-1690.	10.7	92
90	The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans. Hereditary Cancer in Clinical Practice, 2019, 17, 1.	1.5	13

#	ARTICLE	IF	CITATIONS
91	Predictive and Prognostic Value of 18F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2019, 9, 12215.	3.3	3
92	Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. <i>European Journal of Cancer</i> , 2019, 120, 65-74.	2.8	33
93	DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. <i>Nature Communications</i> , 2019, 10, 4278.	12.8	263
94	Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea. <i>BMC Cancer</i> , 2019, 19, 84.	2.6	8
95	Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 193-202.	1.1	104
96	Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor. <i>Clinical Lung Cancer</i> , 2019, 20, 215-221.	2.6	16
97	Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma. <i>Lung Cancer</i> , 2019, 134, 7-15.	2.0	38
98	Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma. , 2019, 7, 128.		27
99	Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, e190339.	7.1	55
100	Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1341-1349.	2.5	19
101	Clinical Characteristics and Prognostic Factors of Lung Cancer in Korea: A Pilot Study of Data from the Korean Nationwide Lung Cancer Registry. <i>Tuberculosis and Respiratory Diseases</i> , 2019, 82, 118.	1.8	45
102	Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer. <i>Lung Cancer</i> , 2019, 130, 87-92.	2.0	39
103	Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. <i>International Journal of Cancer</i> , 2019, 145, 2433-2439.	5.1	26
104	Sedation for terminally ill cancer patients. <i>Medicine (United States)</i> , 2019, 98, e14278.	1.0	12
105	Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, e60-e67.	1.3	2
106	The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2144-2154.	7.0	134
107	A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 255-266.	2.5	96
108	Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8514-8514.	1.6	10

#	ARTICLE	IF	CITATIONS
109	Deep learning-based predictive biomarker for immune checkpoint inhibitor response in metastatic non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9094-9094.	1.6	1
110	ALINA: A phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB-III A anaplastic lymphoma kinase-positive (<i>ALK</i>+) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS8569-TPS8569.	1.6	39
111	EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 493-501.	3.0	30
112	Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 408-412.	3.0	15
113	Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea. <i>Cancer Research and Treatment</i> , 2019, 51, 623-631.	3.0	40
114	Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data. <i>Cancer Research and Treatment</i> , 2019, 51, 727-736.	3.0	18
115	A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. <i>Cancer Research and Treatment</i> , 2019, 51, 718-726.	3.0	10
116	Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance. <i>Cancer Research and Treatment</i> , 2019, 51, 737-747.	3.0	53
117	Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 769-776.	3.0	9
118	Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014. <i>Cancer Research and Treatment</i> , 2019, 51, 1400-1410.	3.0	49
119	Severe immune-related adverse events in anti-PD-1-treated patients are clustered into distinct subtypes by peripheral blood T-cell profiles.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2564-2564.	1.6	0
120	Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, e34-e36.	1.1	28
121	Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy. <i>Lung Cancer</i> , 2018, 117, 7-13.	2.0	12
122	Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). <i>British Journal of Cancer</i> , 2018, 118, 648-653.	6.4	31
123	Phase 1b Trial of Ficlatusumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 532-542.	1.6	17
124	KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, e29-e31.	1.1	30
125	Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 106-111.	1.1	203
126	A train the trainer program for healthcare professionals tasked with providing psychosocial support to breast cancer survivors. <i>BMC Cancer</i> , 2018, 18, 45.	2.6	7

#	ARTICLE	IF	CITATIONS
127	Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment. <i>Clinical Breast Cancer</i> , 2018, 18, e1141-e1147.	2.4	24
128	Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. <i>Nature Communications</i> , 2018, 9, 1725.	12.8	122
129	Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea. <i>Lung Cancer</i> , 2018, 119, 36-41.	2.0	7
130	Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and) Tj ETQq0 0 0 rgBTJ /Overlock 10 Tf 50	2.0	26
131	Inadequate treatment practices for pain relief and adverse event management in cancer patients across 10 countries/regions in Asia: a call for greater efforts to improve standards for patient care. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 159-166.	1.1	9
132	<i>PIK3CA</i> Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis. <i>Journal of Breast Cancer</i> , 2018, 21, 382.	1.9	14
133	Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study). <i>European Journal of Cancer</i> , 2018, 103, 127-136.	2.8	10
134	Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer. <i>Oncolmmunology</i> , 2018, 7, e1466768.	4.6	48
135	Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model. <i>PLoS ONE</i> , 2018, 13, e0194730.	2.5	18
136	Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 737-745.	2.5	27
137	Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy?. <i>Journal of Breast Cancer</i> , 2018, 21, 206.	1.9	8
138	Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial. <i>Lung Cancer</i> , 2018, 124, 293-297.	2.0	12
139	Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , 2018, 122, 160-164.	2.0	10
140	A phase II trial of the panâ€HER inhibitor poziotinib, in patients with HER2â€positive metastatic breast cancer who had received at least two prior HER2â€directed regimens: results of the NOV120101â€203 trial. <i>International Journal of Cancer</i> , 2018, 143, 3240-3247.	5.1	46
141	Characteristics and Outcome of ROS1-Positive Nonâ€Small Cell Lung Cancer Patients in Routine Clinical Practice. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1373-1382.	1.1	77
142	Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1106-1112.	1.1	42
143	Incidence of Diabetes After Cancer Development. <i>JAMA Oncology</i> , 2018, 4, 1099.	7.1	96
144	Distress and body image due to altered appearance in posttreatment and active treatment of breast cancer patients and in general population controls. <i>Palliative and Supportive Care</i> , 2018, 16, 137-145.	1.0	19

#	ARTICLE	IF	CITATIONS
145	YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results.. Journal of Clinical Oncology, 2018, 36, 9033-9033.	1.6	2
146	An open-label, multicenter, phase II single arm trial of osimertinib in non-small cell lung cancer patients with uncommon EGFR mutation (KCSG-LU15-09).. Journal of Clinical Oncology, 2018, 36, 9050-9050.	1.6	15
147	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2018, 36, 9072-9072.	1.6	5
148	Hyperprogression after immunotherapy: Clinical implication and genomic alterations in advanced non-small cell lung cancer patients (NSCLC).. Journal of Clinical Oncology, 2018, 36, 9075-9075.	1.6	19
149	Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01). Journal of Pathology and Translational Medicine, 2018, 52, 148-156.	1.1	15
150	Clinical outcomes of EGFR exon 20 insertion in advanced NSCLC in Korea.. Journal of Clinical Oncology, 2018, 36, e21136-e21136.	1.6	0
151	Monitoring peripheral blood PD-1+CD8+T cells to predict response to anti-PD-1 therapy in solid tumors.. Journal of Clinical Oncology, 2018, 36, e24115-e24115.	1.6	0
152	Osimertinib for the treatment of non-small cell lung cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 225-231.	1.8	4
153	EGFR TKI combination with immunotherapy in non-small cell lung cancer. Expert Opinion on Drug Safety, 2017, 16, 465-469.	2.4	156
154	A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy. Breast Cancer Research and Treatment, 2017, 164, 617-625.	2.5	10
155	An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer. Expert Review of Molecular Diagnostics, 2017, 17, 933-942.	3.1	5
156	Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. Cancer Chemotherapy and Pharmacology, 2017, 80, 591-598.	2.3	47
157	Prevalence and detection of low-allele-fraction variants in clinical cancer samples. Nature Communications, 2017, 8, 1377.	12.8	137
158	Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1806-1813.	1.1	36
159	Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 329-336.	1.1	12
160	Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review. Journal of Pain Research, 2017, Volume 10, 1963-1972.	2.0	33
161	Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period. Journal of Pathology and Translational Medicine, 2017, 51, 69-78.	1.1	21
162	Discomfort related to Peripherally Inserted Central Catheters in Cancer Patient. Asian Oncology Nursing, 2017, 17, 229.	0.6	4

#	ARTICLE	IF	CITATIONS
163	Alectinib versus crizotinib in treatment-naive advanced <i>ALK</i> -positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA9008-LBA9008.	1.6	6
164	Alectinib versus crizotinib in treatment-naive advanced <i>ALK</i> -positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA9008-LBA9008.	1.6	16
165	The effect of androgen receptor expression on clinical characterization of metastatic breast cancer. <i>Oncotarget</i> , 2017, 8, 8693-8706.	1.8	7
166	Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes. <i>Oncotarget</i> , 2017, 8, 27997-28007.	1.8	23
167	Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response. <i>Oncotarget</i> , 2017, 8, 47400-47411.	1.8	21
168	Mutational status of <i>TP53</i> defines the efficacy of Wee1 inhibitor AZD1775 in <i>KRAS</i> -mutant non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 67526-67537.	1.8	28
169	The feasibility of using small biopsy samples from lung cancer for targeted next-generation sequencing.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20584-e20584.	1.6	1
170	A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10108-10108.	1.6	0
171	Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience. <i>Cancer Research and Treatment</i> , 2017, 49, 880-889.	3.0	2
172	Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes. <i>Journal of Breast Cancer</i> , 2016, 19, 169.	1.9	11
173	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). <i>Oncotarget</i> , 2016, 7, 6984-6993.	1.8	134
174	Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 1338-1350.	3.0	56
175	Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea. <i>Cancer Research and Treatment</i> , 2016, 48, 1382-1388.	3.0	10
176	The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. <i>Journal of Thoracic Disease</i> , 2016, 8, 3175-3186.	1.4	4
177	Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series. <i>PLoS ONE</i> , 2016, 11, e0163254.	2.5	6
178	The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC). <i>PLoS ONE</i> , 2016, 11, e0149432.	2.5	3
179	The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 14803-14813.	1.8	49
180	Efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with <i>FGFR1</i> amplification: A single-arm, phase 2 study. <i>Cancer</i> , 2016, 122, 3024-3031.	4.1	72

#	ARTICLE	IF	CITATIONS
181	The relationship between nuclear factor (NF)- κ B family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment. <i>Scientific Reports</i> , 2016, 6, 31804.	3.3	44
182	Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2051-2052.	1.1	6
183	Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria. <i>Lung Cancer</i> , 2016, 96, 48-51.	2.0	4
184	AZD9291 overcomes T790M-mediated resistance through degradation of EGFR L858R/T790M in non-small cell lung cancer cells. <i>Investigational New Drugs</i> , 2016, 34, 407-415.	2.6	13
185	Do New pN Subclassifications Proposed by IASLC's Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2202-2207.	1.1	3
186	Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. <i>Medical Oncology</i> , 2016, 33, 97.	2.5	39
187	Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor. <i>Lung Cancer</i> , 2016, 100, 24-29.	2.0	5
188	Gene Expression Profiling of Breast Cancer Brain Metastasis. <i>Scientific Reports</i> , 2016, 6, 28623.	3.3	51
189	Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency. <i>Scientific Reports</i> , 2016, 6, 33035.	3.3	24
190	Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 475-489.	2.5	33
191	Prognostic value of ERBB4 expression in patients with triple negative breast cancer. <i>BMC Cancer</i> , 2016, 16, 138.	2.6	39
192	Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study. <i>Cancer Imaging</i> , 2016, 16, 5.	2.8	27
193	Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. <i>Journal of Thoracic Oncology</i> , 2016, 11, e1-e4.	1.1	76
194	Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, e45-e47.	1.1	98
195	Pembrolizumab for the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 397-406.	3.1	56
196	Reply to Y.H. Kim and M. Mishima. <i>Journal of Clinical Oncology</i> , 2016, 34, 768-768.	1.6	0
197	Limited Supraclavicular Radiation Field in Breast Cancer With \geq 10 Positive Axillary Lymph Nodes. <i>Clinical Breast Cancer</i> , 2016, 16, e15-e21.	2.4	1
198	Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 661-668.	1.6	548

#	ARTICLE	IF	CITATIONS
199	A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. <i>Clinical Cancer Research</i> , 2016, 22, 2139-2145.	7.0	30
200	A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement. <i>Journal of Clinical Oncology</i> , 2016, 34, 9013-9013.	1.6	16
201	Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). <i>Oncotarget</i> , 2016, 7, 36311-36320.	1.8	44
202	Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases. <i>Journal of Pathology and Translational Medicine</i> , 2016, 50, 258-263.	1.1	50
203	Combination of CDK4/6 inhibitor, LY2835219, and mTOR inhibitor to synergistically suppress the growth of head and neck squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, e14118-e14118.	1.6	0
204	Efficacy and safety of alectinib in ALK+ non-small-cell lung cancer (NSCLC): Pooled data from two pivotal phase II studies (NP28673 and NP28761). <i>Journal of Clinical Oncology</i> , 2016, 34, e20507-e20507.	1.6	1
205	Current practices in cancer pain management in Asia: a survey of patients and physicians across 10 countries. <i>Cancer Medicine</i> , 2015, 4, 1196-1204.	2.8	60
206	Proportion and Clinical Outcomes of Postoperative Radiotherapy Omission after Breast-Conserving Surgery in Women with Breast Cancer. <i>Journal of Breast Cancer</i> , 2015, 18, 50.	1.9	5
207	Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay. <i>Oncotarget</i> , 2015, 6, 24499-24510.	1.8	7
208	Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21. <i>Oncologist</i> , 2015, 20, 1440-1447.	3.7	12
209	Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea. <i>Breast</i> , 2015, 24, 213-217.	2.2	23
210	Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments. <i>Clinical Breast Cancer</i> , 2015, 15, 512-518.	2.4	9
211	Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2450-2456.	1.6	61
212	Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). <i>Breast Cancer Research and Treatment</i> , 2015, 152, 77-85.	2.5	17
213	Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. <i>Journal of Clinical Oncology</i> , 2015, 33, 2660-2666.	1.6	215
214	Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. <i>Lung Cancer</i> , 2015, 90, 261-266.	2.0	4
215	Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer. <i>Journal of Neuro-Oncology</i> , 2015, 125, 331-338.	2.9	20
216	Prognostic Modeling in Pathologic N1 Breast Cancer Without Elective Nodal Irradiation After Current Standard Systemic Management. <i>Clinical Breast Cancer</i> , 2015, 15, e197-e204.	2.4	6

#	ARTICLE	IF	CITATIONS
217	Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, e287-e292.	2.4	10
218	Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 585-585.	1.6	4
219	Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8008-8008.	1.6	18
220	A phase Ib/II study of afatinib in combination with nimotuzumab in non-small cell lung cancer patients with acquired resistance to gefitinib or erlotinib.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8086-8086.	1.6	1
221	Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 30929-30938.	1.8	10
222	Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer. <i>Oncotarget</i> , 2015, 6, 32027-32038.	1.8	36
223	The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis. <i>Oncotarget</i> , 2015, 6, 33358-33368.	1.8	24
224	Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. <i>Oncotarget</i> , 2015, 6, 43731-43742.	1.8	63
225	Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 645-652.	3.0	7
226	Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer. <i>Cancer Research and Treatment</i> , 2015, 47, 765-773.	3.0	4
227	Experience and difficulties from working with cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20603-e20603.	1.6	0
228	Cancer pain management practices and their impact on quality of life for Asian cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6531-6531.	1.6	0
229	Contribution of clinical trials to improved clinical outcomes for patients with metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e12596-e12596.	1.6	0
230	Dynamic serial monitoring of EGFR mutations in plasma DNA samples in EGFR mutant NSCLC patients treated with EGFR TKI.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8078-8078.	1.6	3
231	Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR. <i>Oncologist</i> , 2014, 19, 702-703.	3.7	11
232	Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. <i>Lung Cancer</i> , 2014, 83, 259-264.	2.0	30
233	Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. <i>European Journal of Cancer</i> , 2014, 50, 698-705.	2.8	32
234	A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): Paclitaxel plus carboplatin versus vinorelbine plus cisplatin. <i>Lung Cancer</i> , 2014, 84, 51-55.	2.0	28

#	ARTICLE	IF	CITATIONS
235	A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CChelN).. Journal of Clinical Oncology, 2014, 32, 7500-7500.	1.6	5
236	A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians. Cancer Research and Treatment, 2014, 46, 131-140.	3.0	7
237	Intra-tumoral Metastatic Double Primary Carcinoma: Synchronous Metastatic Tumor in Lung from Breast and Thyroid Carcinoma. Cancer Research and Treatment, 2014, 46, 200-203.	3.0	1
238	Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes. SpringerPlus, 2013, 2, 136.	1.2	18
239	A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy. Lung Cancer, 2013, 82, 455-460.	2.0	30
240	Micropapillary Mucinous Adenocarcinoma of the Lung: A Brief Case Report. Korean Journal of Pathology, 2013, 47, 603.	1.3	3
241	Prognostic factors for survivals from first relapse in breast cancer patients: analysis of deceased patients. Radiation Oncology Journal, 2013, 31, 222.	1.5	21
242	Tumor Lysis Syndrome in a Solid Tumor: A Case Report of a Patient with Invasive Thymoma. Cancer Research and Treatment, 2013, 45, 343-348.	3.0	6
243	Comparison of clinical outcome between gefitinib and erlotinib treatment in patients with non-small cell lung cancer harboring an epidermal growth factor receptor exon 19 or exon 21 mutations.. Journal of Clinical Oncology, 2013, 31, e19051-e19051.	1.6	0
244	A Dramatic Response to Crizotinib in a Nonâ€“Small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK. Journal of Thoracic Oncology, 2012, 7, e36-e38.	1.1	87
245	A phase III, multicenter, randomized trial of maintenance versus observation after achieving clinical response in patients with metastatic breast cancer who received six cycles of gemcitabine plus paclitaxel as first-line chemotherapy (KCSG-BR 0702, NCT00561119).. Journal of Clinical Oncology, 2012, 30, 1003-1003.	1.6	2
246	A prospective, phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors.. Journal of Clinical Oncology, 2012, 30, 7104-7104.	1.6	0
247	Bone Marrow Cellularity Is a Single Most Important Independent Prognostic Factor In AML Patients with t(8;21). Blood, 2010, 116, 1707-1707.	1.4	1
248	The Prognostic Utility of the Simplified Acute Physiology Score II (SAPS II) and the Sequential Organ Failure Assessment (SOFA) Score for Hemato-Oncology Patients Admitted to the Intensive Care Unit. The Korean Journal of Critical Care Medicine, 2009, 24, 4.	0.2	1
249	Ets-1 upregulates HER2-induced MMP-1 expression in breast cancer cells. Biochemical and Biophysical Research Communications, 2008, 377, 389-394.	2.1	45
250	A Comparison of Clinical Outcomes for Breast-conserving Treatment and Mastectomy for Early Breast Cancer. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2008, 26, 10.	0.1	2
251	The Clinical Guidelines for Myelodysplastic Syndrome. The Korean Journal of Hematology, 2007, 42, 71.	0.7	1
252	Generation and Qualification of Functionally Active Leukemia-derived DCs from Malignant Blasts in Acute Leukemia. The Korean Journal of Hematology, 2007, 42, 264.	0.7	0

#	ARTICLE	IF	CITATIONS
253	Preliminary Results of a Prospective Multicenter Phase III Trial Comparing High-Dose and Standard-Dose Daunorubicin for Induction of Complete Remission (CR) in Acute Myeloid Leukemia (AML).. Blood, 2007, 110, 1833-1833.	1.4	0
254	Allogeneic Hematopoietic Cell Transplantation (HCT) for Acute Leukemia in First Relapse or Second Remission.. Blood, 2005, 106, 5415-5415.	1.4	0